北米の前立腺がん診断市場 – 業界動向と2028年までの予測

市場分析と洞察: 北米の前立腺がん診断市場

前立腺がん診断市場は、2021年から2028年の予測期間に市場成長を遂げると予想されています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に12.9％のCAGRで成長し、2028年までに36億3,144万米ドルに達すると分析しています。疾患負担への注目の高まりと疾患に関する意識の高まりは、予測期間に前立腺がん診断市場を推進する主な原動力です。

前立腺がんは、前立腺の細胞が異常な速度で増殖し始めたときに始まり、その状態は前立腺がんとして知られています。前立腺は男性にのみ存在する腺です。精液の一部である液体の一部を作ります。前立腺がんの診断は、主に早期段階でがんを検出し、生存率を高めることができる将来の治療アプローチを実施する技術です。

The development of prostate cancer is closely linked with the age, with the increasing geriatric population, there is the significant increase in the incidence for prostate cancer. This will increase the demand for the diagnostics product for the detection of the disease and is expected to act as a driver for the prostate cancer diagnostics market. The PSA testing is one of the primary tests that are used for prostate cancer detection. However, the contradictions between the government and medical services provider for using PSA and related test is expected to restraint the prostate cancer diagnostics market. The market have a huge potential to grow and with the entry of new market players trying to enter market using business expansion via distribution agreements and have invested towards the prostate cancer diagnosis is expected to increase the market size and will act as opportunity for the prostate cancer diagnostics market. The barrier related with conducting the cancer diagnostics test may affect the life of the population and this is one of the most difficult parts to overcome with respect to the low income countries, thus this is affecting the diagnostics community and acting as a challenge for the prostate cancer diagnostics market.  

The prostate cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Prostate Cancer Diagnostics Market Scope and Market Size

The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of product type, the prostate cancer diagnostics market is segmented into instruments, reagents & consumables and accessories. In 2021, reagents & consumables segment is dominating in the prostate cancer diagnostics market as it includes the PSA testing products which is the primary test recommended for preliminary testing.
• On the basis of diagnostics type, the prostate cancer diagnostics market is segmented into preliminary screening tests and confirmatory tests. In 2021, preliminary screening tests segment is dominating in the prostate cancer diagnostics market as the number of preliminary tests surpass the number of confirmatory tests by significant percentage. 
• On the basis of age group, the prostate cancer diagnostics market is segmented into adult, pediatric and geriatrics. In 2021, geriatrics segment is dominating in the prostate cancer diagnostics market as around 60% of cases are diagnosed in men over 65 year of age.
• On the basis of type, the prostate cancer diagnostics market is segmented into prostatic adenocarcinoma, small cell carcinoma and others. In 2021, prostatic adenocarcinoma segment dominates the prostate cancer diagnostics market because more than 95 percent of prostate cancers are adenocarcinomas which develop in the gland cells and line of the prostate gland.
• On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III.
• On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market. 
• On the basis of end users, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as the segment is specialized in conducting various prostate cancer diagnostics.
• On the basis of distribution channel, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs.

Prostate Cancer Diagnostics Market Country Level Analysis

The prostate cancer diagnostics market is analysed and market size information is provided by the country, product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel as referenced above.

The countries covered in the North America prostate cancer diagnostics market report are the U.S., Canada and Mexico.

The North America region holds the majority of the share in the prostate cancer diagnostics market and is expected to witness the CAGR during the forecast period due to increasing number of diagnosis tests in the region. The U.S. is expected to dominate in the North America prostate cancer diagnostics market due to the increasing awareness regarding the disease.  

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by Manufacturers is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market 

The prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2011 to 2019. 

Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis

The prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market. 

北米の前立腺がん診断市場レポートを提供している主要企業には、F. Hoffmann-La Roche Ltd、ACON Laboratories, Inc.、Teco Diagnostics、Hologic Inc.、Accuquik Test Kits、MDxHealthcare、Abbott、Siemens Healthcare GmbH、OPKO Health Inc.、Myraid Genetics, Inc.、DiaSorin SpA、Beckman Coulter, Inc. (Danaher の子会社)、Genomic Health, Inc. (Exact Sciences Corporation の子会社)、bioMérieux SA、Metamark Genetics, Inc.、Fujirebio、Eurolyser Diagnostica GmbH など、国内外の企業があります。DBMR のアナリストは、競争力を理解し、各競合他社の競合分析を個別に提供しています。

世界中の企業によって多くの製品の発売や契約も開始されており、前立腺がん診断市場の成長も加速しています。

例えば、  

• 2021年1月、Hologic Inc.は、Biotheranostics, Inc.を2億3,000万米ドルで買収することに合意したことを発表しました。この会社は、転移性癌および乳癌の分子診断検査を提供しています。買収が完了すると、Hologic Inc.は癌患者のための世界的な腫瘍学検出で飛躍的なスタートを切り、会社の収益に貢献することになります。

市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、前立腺がん診断市場における企業市場が強化され、組織にとっても前立腺がん診断市場への提供を改善するメリットがもたらされます。   

SKU-60334